Zenas BioPharma ZBIO 深 滬
已收盤 07-31 16:00:00 美东时间
31.44
-0.830
-2.57%
華盛通- 最 高32.95
- 今 開32.69
- 成交量 45.22万股
- 最 低 30.60
- 昨 收 32.27
- 總市值 19.85亿
- 52周最高 44.60
- 市盈率 靜 --
- 換手率 0.72%
- 52周最低 13.50
- 委 比 66.39%
- 總股本 6313.34万
- 歷史最高 44.60
- 量 比 0.59
- 振 幅 7.28%
- 歷史最低 5.83
- 每 手 1
- 風險率 6.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 17, 2026 – Zenas BioPharma, Inc. granted stock options and restricted stock units to newly hired employees as inducement grants under Nasdaq Listing Rule 5635(c)(4). The Stock Options, totaling 35,750 shares with an exercise price of $29.41, vest over four years. The RSUs, totaling 79,050 units, vest in four equal installments annually. Both grants are subject to continued employment and governed by the Company’s 2026 Inducem...
07-17 20:15
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Friday. Shares of Lennar Corp (NYSE:LEN) fell sharply in pre-market trading after the company posted mixed second-quarter results. Lennar reported quarterly adjusted earnings of $1.31 per share, which beat...
06-12 20:02
Zenas BioPharma Submits An FDA Biologics License Application For Obexelimab In Immunoglobulin G4-Related Disease
IgG4-RD is a debilitating chronic fibro-inflammatory disease affecting multiple organ systems, often resulting in irreversible tissue damage and organ failure. Obexelimab, an investigational therapy, is a bifunctional
05-28 19:14
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Zenas BioPharma Does First Patient In Its Phase 1 Trial Of ZB021, A Novel Oral IL-17AA/AF Inhibitor
The ZB021 Phase 1 trial is supported by robust preclinical data demonstrating a desirable pharmacology and toxicology profile. In addition to potent inhibition of IL-17AA/AF signaling, and anti-inflammatory activity
05-13 18:52
Zenas BioPharma Q1 EPS $(1.46) Misses $(1.17) Estimate
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.17) by 24.79 percent. This is a 82.5 percent decrease over losses of $(0.80) per share from
05-13 18:32
Alpha Buying: Insider Conviction in High-Risk Biotech
Insider buying matters in every industry, but it carries a special weight in bi...
05-08 00:04
Zenas BioPharma shares are trading lower after the company announced it commenced an underwritten public offering of convertible senior notes and shares of its common stock.
Zenas BioPharma shares are trading lower after the company announced it commenc...
03-27 04:35
